Literature DB >> 10332053

Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination.

Y Tabata1, Y Noda, Y Matsui, Y Ikada.   

Abstract

Tumor targeting of recombinant human tumor necrosis factor alpha (TNF) and consequently an enhanced anti-tumor effect were achieved through conjugation with dextran having metal chelating, diethylenetriaminepentaacetic acid (DTPA) residues based on metal coordination. A simple mixing with the DTPA-dextran in an aqueous solution containing Cu2+ enabled TNF to coordinately conjugate to dextran. Following intravenous (i.v.) injection into tumor-bearing mice, the TNF-DTPA-dextran conjugate caused a significantly higher tumor accumulation of TNF and the longer retention period than free TNF or its mixture with the DTPA-dextran. Intravenous injection of the TNF-DTPA-dextran conjugate suppressed tumor growth to a significantly greater extent than that of free TNF at a lower injection dose. It is concluded that dextran conjugation based on Cu2+ coordination is a promising way to enhance the anti-tumor effect of TNF as a result of its passive tumor targeting.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10332053     DOI: 10.1016/s0168-3659(98)00190-4

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  3 in total

1.  Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Authors:  Mithun M Shenoi; Isabelle Iltis; Jeunghwan Choi; Nathan A Koonce; Gregory J Metzger; Robert J Griffin; John C Bischof
Journal:  Mol Pharm       Date:  2013-04-17       Impact factor: 4.939

Review 2.  Improvement in the Pharmacological Profile of Copper Biological Active Complexes by Their Incorporation into Organic or Inorganic Matrix.

Authors:  Mihaela Badea; Valentina Uivarosi; Rodica Olar
Journal:  Molecules       Date:  2020-12-10       Impact factor: 4.411

3.  Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.

Authors:  D Azria; C Larbouret; V Garambois; A Kramar; P Martineau; B Robert; N Aillères; M Ychou; J B Dubois; A Pèlegrin
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.